Board of Directors

Kathleen_PHM3052_LowRes

Dr Kathleen Metters

Independent Chair

  • Former Senior Vice President and Head of Worldwide Basic Research for Merck & Co. with oversight of all the company’s global research projects
  • In a subsequent role at Merck &Co she led work on External Discovery and Preclinical Sciences
  • Former CEO of biopharmaceutical company Lycera Corp
Simon_PHM3183_LowRes

Dr Simon Green

Non-Executive Director

  • Experienced senior global pharma executive with 30 years’ of experience in the biotechnology industry.
  • Actively involved in CSL’s global expansion over a 17-year period where he held roles as Senior Vice President, Global Plasma R&D and General Manager of CSL’s manufacturing plants in Germany and Australia.
  • Prior to joining CSL he worked in the USA at leading biotechnology companies Genentech Inc and Chiron Corporation.
Gary_PHM3132_LowRes

Gary Phillips

Chief Executive Officer

  • 30+ years’ of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia
  • Joined Pharmaxis in 2003 and was appointed Chief Executive Officer in March 2013 at which time he was Chief Operating Officer
  • Previously held country and regional management roles at Novartis – Hungary, Asia Pacific and Australia
Hashan_PHM3012_LowRes

Hashan De Silva

Non-Executive Director

  • Experienced life sciences investment professional with extensive knowledge of the biotech, pharmaceutical and medical technology sectors.
  • Worked as associate healthcare analyst at Macquarie Group and lead healthcare analyst at CLSA Australia before joining Karst Peak Capital in February 2021 as head of healthcare research.
  • Prior to moving into life science investment Hashan worked at Eli Lilly in various roles focused on the commercialisation of new and existing pharmaceuticals.

Management team

Gary_PHM3132_LowRes

Gary Phillips

Chief Executive Officer

  • 30+ years’ of operational management experience in the pharmaceutical and healthcare industry in Europe, Asia and Australia
  • Previously held country and regional management roles at Novartis – Hungary, Asia Pacific and Australia
Tim-Luscombe

Tim Luscombe

Chief Financial Officer

  • 10 years of finance and commercial experience working with public and private companies in Australia and abroad.
  • Currently serves as a CFO and Company Secretary for several ASX-listed, public unlisted and private companies.
Jana_PHM3257_LowRes

Jana Baskar

Chief Medical Officer

  • 20+ years’ experience both in clinical medicine and the biopharmaceutical industry
  • Former Medical Director at Novartis Oncology in Australia; former Medical Director for IQVIA in Australia and New Zealand
Wolfgang_PHM2907_LowRes

Wolfgang Jarolimek

Head of Drug Discovery

  • 20+ years’ experience in pharmaceutical drug discovery and published more than 30 peer reviewed articles
  • Previously Director of Assay Development and Compound Profiling at the GlaxoSmithKline Centre of Excellence in Drug Discovery in Verona, Italy
David_PHM3218_LowRes

David McGarvey

Company Secretary

  • 30+ years of experience building Australian based companies from inception to globally successful enterprises
  • Previously Chief Financial Officer of the Filtration and Separations Division of US Filter (1998-2002), and Memtec Limited (1985-1998)
Kristen_PHM3282_LowRes

Kristen Morgan

Head of Medical and Regulatory Affairs

  • More than  20 years’ experience in the pharmaceutical industry
  • Previously held a senior role in medical affairs at Sanofi-Aventis, and a commercial sales role at GlaxoSmithKline
Dieter_PHM2943_LowRes

Dieter Hamprecht

Head of Chemistry

  • 20+ years’ experience with small molecule and peptide drug discovery, contributed to greater than 10 drug candidates brought to development and co-inventor of 50 patent families, co-author of 30+ scientific publications
  • Previously Managing Director – Boehringer Ingelheim’s research group in Milan

Syntara

Syntara is a clinical stage drug development company focused on haematological malignancies.